Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05885607 · ClinicalTrials.gov registry record
Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure
A clinical trial, sponsored by University of Pennsylvania.
- Active
- Registry status
- 40
- Enrollment target
NCT05885607: Active study, sponsored by University of Pennsylvania.
NCT05885607 is a clinical trial that is active but no longer recruiting, run by University of Pennsylvania. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05885607 is active but no longer recruiting, sponsored by University of Pennsylvania.
- ACTIVE NOT RECRUITING
- Registry status
- 40 participants
- Enrollment target
Study Summary
The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors. The main question it aims to answer is: * What are the impacts of SGLT2 inhibition on systemic metabolomic and proteomic profiles? Participants will be asked to do the following before and after being prescribed a SGLT2i. * Six-minute walk testd * Calf MRI with plantar flexion exercise * Blood sample collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2023-06-27 |
| Est. Completion | 2027-06-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05885607
The ClinicalTrials.gov registry entry for NCT05885607 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT05885607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05885607 about?
NCT05885607 is a clinical study titled "Early Metabolic Adaptations to SGLT2 Inhibition in Heart Failure". The goal of this observational study is to learn about SGLT2 inhibition medications in patients with symptomatic heart failure who are clinically prescribed FDA-approved SGLT2 inhibitors. The main question it aims to answer is: * What are the impacts of SGLT2 inhibition on systemic metabolomic and ...
What is the current status of trial NCT05885607?
This trial is currently active not recruiting. The enrollment target is 40 participants. The study started on 2023-06-27. Estimated completion is 2027-06-30.
Who is sponsoring clinical trial NCT05885607?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.